345 related articles for article (PubMed ID: 25732170)
1. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer.
Queiroz ACM; Fabri V; Mantoan H; Sanches SM; Guimarães APG; Ribeiro ARG; da Nogueira Silveira Lima JP; Chen MJ; Baiocchi G; da Costa AABA
Eur J Obstet Gynecol Reprod Biol; 2019 Apr; 235():6-12. PubMed ID: 30771718
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.
Kim SW; Chun M; Ryu HS; Chang SJ; Kong TW; Lee EJ; Lee YH; Oh YT
Strahlenther Onkol; 2017 Jul; 193(7):534-542. PubMed ID: 28357468
[TBL] [Abstract][Full Text] [Related]
4. Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: A special focus on lymph nodes metastases.
Wang W; Liu X; Meng Q; Zhang F; Hu K
PLoS One; 2019; 14(4):e0214498. PubMed ID: 30986236
[TBL] [Abstract][Full Text] [Related]
5. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
6. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
[TBL] [Abstract][Full Text] [Related]
7. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
8. Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer.
Marchetti C; De Felice F; Di Pinto A; Romito A; Musella A; Palaia I; Monti M; Tombolin V; Muzii L; Benedetti Panici P
Cancer Res Treat; 2018 Jul; 50(3):768-776. PubMed ID: 28724282
[TBL] [Abstract][Full Text] [Related]
9. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.
Fakhry C; Zhang Q; Nguyen-Tân PF; Rosenthal DI; Weber RS; Lambert L; Trotti AM; Barrett WL; Thorstad WL; Jones CU; Yom SS; Wong SJ; Ridge JA; Rao SSD; Bonner JA; Vigneault E; Raben D; Kudrimoti MR; Harris J; Le QT; Gillison ML
J Clin Oncol; 2017 Dec; 35(36):4057-4065. PubMed ID: 28777690
[TBL] [Abstract][Full Text] [Related]
11. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study.
Kang S; Nam BH; Park JY; Seo SS; Ryu SY; Kim JW; Kim SC; Park SY; Nam JH
J Clin Oncol; 2012 Jul; 30(19):2369-74. PubMed ID: 22614984
[TBL] [Abstract][Full Text] [Related]
12. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.
Monk BJ; Tian C; Rose PG; Lanciano R
Gynecol Oncol; 2007 May; 105(2):427-33. PubMed ID: 17275889
[TBL] [Abstract][Full Text] [Related]
13. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
16. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.
Rose PG; Ali S; Watkins E; Thigpen JT; Deppe G; Clarke-Pearson DL; Insalaco S;
J Clin Oncol; 2007 Jul; 25(19):2804-10. PubMed ID: 17502627
[TBL] [Abstract][Full Text] [Related]
18. Definitive concurrent chemoradiotherapy in cervical cancer--a University of Malaya Medical Centre experience.
Zamaniah WI; Mastura MY; Phua CE; Adlinda A; Marniza S; Rozita AM
Asian Pac J Cancer Prev; 2014; 15(20):8987-92. PubMed ID: 25374241
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Liu J; Tang G; Zhou Q; Kuang W
Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
[TBL] [Abstract][Full Text] [Related]
20. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.
Chen JL; Huang CY; Huang YS; Chen RJ; Wang CW; Chen YH; Cheng JC; Cheng AL; Kuo SH
Acta Obstet Gynecol Scand; 2014 Jul; 93(7):661-8. PubMed ID: 24666257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
